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Mechanisms of cell uptake and toxicity of the
anticancer drug cisplatin
Nasma D. Eljack,a Ho-Yu M. Ma,a Janine Drucker,b Clara Shen,a
Trevor W. Hambley,a Elizabeth J. New,a Thomas Friedrichb and Ronald J. Clarke†*a
Two major issues which hamper the use of the anticancer drug cisplatin are the development of cancer cell
resistance and its nephrotoxicity. One possible mechanism by which resistance is reported to develop is a
reduction in drug uptake across the cell membrane. While the passive uptake of cisplatin has long been cited
as an important contribution, far greater attention has been given to active modes of uptake, particularly in
recent research. Using unilamellar lipid vesicles together with the stopped-flow kinetic method we show here
that the permeability coeﬃcient of cisplatin increases significantly with the chloride concentration of the
medium. This supports the hypothesis that cisplatin can enter cells via passive permeation through the lipid
phase of the membrane, but becomes trapped within the cytoplasm because dissociation of chloride ligands
yields a membrane-impermeant positively-charged aqua derivative. This is important evidence for a major
role of passive membrane diﬀusion in the uptake of cisplatin, and suggests that reduced cell uptake is
unlikely to be a significant mechanism leading to the development of drug resistance. Studies of rubidium ion
uptake into the cytoplasm of Xenopus oocytes via the Na+,K+-ATPase show significant inhibition of this ion
pump when cisplatin is present in the cytoplasm. Because Na+,K+-ATPase activity is essential to the survival
of all animal cells, e.g. via maintenance of cell volume, and the Na+,K+-ATPase is expressed at particularly
high levels within the membranes of kidney tubules where it plays a crucial role in nutrient reabsorption,
these results suggest that cisplatin-induced inhibition of the Na+,K+-ATPase is a likely contributing cause for
the nephrotoxicity of cisplatin.
Introduction
Cisplatin (cis-diamminedichloridoplatinum(II), cis-[PtCl2(NH3)2])
can be considered one of the most eﬀective chemotherapeutic
agents, utilized for the treatment of a variety of solid human
tumours. Once in the cytoplasm of a cell, it is well established
that cisplatin undergoes a conversion to its aquated derivative
cis-[PtCl(NH3)2(OH2)]
+, driven by the approximately 13-fold lower
concentration of chloride in the cell cytoplasm relative to the
extracellular fluid.1,2 This aquated derivative is recognised to be
responsible for the anti-cancer activity of the drug, because of its
ability to react with DNA, eventually forming a bifunctional adduct
which inhibits DNA replication and initiates cell apoptosis.3
Two major problems exist, however, in the clinical use of
cisplatin. One is the development of tumour resistance to the
drug during therapy, leading to treatment failure.4–7 The other
is the drug’s nephrotoxicity, which limits the dose that can be
administered.8 It is clear that much remains to be understood
about the biophysical interactions of cisplatin with the cell
membrane and with membrane-bound proteins.
Considering first the problem of resistance, at present the
dominant mechanism accounting for clinically acquired resis-
tance is still unknown. However, from experiments with cell
lines to which cisplatin was administered at concentrations
above the normal pharmacological level, a number of factors
have been identified as contributing to resistance.4–7 At this
stage, important mechanisms responsible for the development
of cisplatin resistance appear likely to be: (1) decreased cyto-
plasmic accumulation of cisplatin, (2) increased levels of
glutathione or glutathione-S-transferase activity, (3) increased
levels of cytoplasmic metallothioneins, and (4) enhanced DNA
repair. Here we will concentrate on the first of these possible
mechanisms, i.e., decreased cytoplasmic accumulation of the
drug. Assuming that the drug actually reaches the site of
tumour cells, there are two possible origins for a decrease in
the concentration of cisplatin within the tumour cell cyto-
plasm. One is a decrease in the kinetics of uptake of drug
across the plasma membrane. The other is an increase in the
rate of drug efflux, whether passive or active. To assess the
feasibility that a decrease in drug uptake could contribute to
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the development of resistance, it is important to establish how
cisplatin enters the cell.
Themechanismof cisplatin activity involvingDNAbindingof the
metabolite cis-[PtCl(NH3)2(OH2)]
+, requires that an intact cisplatin
molecule reaches the interior of the cell. Based on indirect evidence
comparing protein expression levels to the amount of cellular Pt
accumulated, it has been suggested that active uptake of cisplatin is
mediatedbymembrane-embeddedproteins including copper trans-
porters, such as CTR1,9 or an organic cation transporter.10 Much
recent attention in the search for new platinum complexes over-
coming resistanceorwith increasedpotencyhas, therefore, focussed
on these active transporters.However, there is increasing skepticism
surrounding protein-mediated cisplatin uptake; recent studies
showing irreversible binding of platinum to the cysteine-rich CTR1
protein11 suggest that it is unlikely that intact cisplatin can be
transported into the cell via CTR1.12 Furthermore, Ivy and Kaplan13
recently reported no increase in the rate of cisplatin entry into a
variety of cells on increasing theexpressionofCTR1.Theyalso found
that the rate of Pt drug uptakewasnot saturable, suggesting that it is
not protein-mediated.
The structure of cisplatin is consistent with passive membrane
diﬀusion; cisplatin has no net charge and therefore would not be
subject to the huge Born energy barrier that prevents small
hydrophilic ions from diﬀusing through the lipid phase of cell
membranes. Hence, cisplatin could possibly enter tumour cells
simply by passive diﬀusion through the lipid matrix of the
membrane. To assess the feasibility of uptake by passive diﬀu-
sion, here we report measurements of the permeability coeﬃcient
of cisplatin across the membranes of synthetic unilamellar lipid
vesicles, i.e., a model membrane system in which proteins are
entirely excluded. Because the plasma membrane of all animal
cells is based on a lipid bilayer matrix, if cisplatin uptake does
occur through the lipid matrix, then reduction in drug uptake is
unlikely to be a means whereby resistance develops, because
lipids are so intrinsic to membrane integrity that they can never
be removed and any modification to the lipid composition is
likely to have an adverse eﬀect on membrane protein function.
The second important problem facing chemotherapy via
cisplatin is the drug’s nephrotoxicity. Recently it has been
reported that cisplatin binds to a cytoplasmic-protruding
domain of the Na+,K+-ATPase and inhibits the activity of the
purified enzyme.14,15 As pointed out by Hulicˇiak et al.,14 the
Na+,K+-ATPase is the only protein present in the plasma
membrane of kidney tubule cells which generates the Na+
concentration gradient across the membrane, which provides
the energy for driving all of the secondary active transporters
responsible for the reabsorption of essential nutrients (e.g.
glucose and amino acids) back into the bloodstream. Thus, if
cisplatin causes a failure of the Na+,K+-ATPase this would lead
to the collapse of the entire nutrient reabsorption machinery
of the kidney. The Na+,K+-ATPase is hence a prime suspect in
cisplatin’s nephrotoxicity. Up to now, however, no tests of the
eﬀects of cisplatin on the Na+,K+-ATPase in intact cells have
been carried out. Therefore, here we report the first measurements
on the influence of cisplatin on the ion pumping activity of the
Na+,K+-ATPase in a cell. For this purpose we have used Xenopus
oocytes, because this system allows an over-expression of the
protein and very precise measurements of ion uptake.
Materials and methods
Materials
1,2-Dioleoyl-sn-glycero-3-phosphocholine (99.9%) was purchased
from Sigma (Castle Hill, NSW, Australia). Tris[hydroxymethyl]-
aminomethane (Tris, 99.9%) and NaCl (99.9%) were from Sigma
and Merck (Darmstadt, Germany), respectively. The purities
and origins of the solvents used were as follows: chloroform
(99.8%, Fluka, Castle Hill, NSW, Australia) and methanol
(99.8%, EM Science, Gibbstown, NJ, USA). Cisplatin (cis-diammine-
dichloridoplatinum(II), cis-[PtCl2(NH3)2]) was synthesized as
described previously.16
Preparation of unilamellar lipid vesicles and size
determination
To prepare unilamellar vesicles, 1 mL of a 0.1 mM solution of
dioleoylphosphatidylcholine (DOPC) in 9/1 v/v chloroform/
methanol was first evaporated with gentle rotation in a 25 mL
round-bottom flask under reduced pressure at room tempera-
ture over 15 minutes using a rotary evaporator. The resultant
lipid film was hydrated by adding 1.0 mL of a 5 mM Tris buﬀer
solution (pH 7.4) containing NaCl (concentrations in the range
10–150 mM) and occasional shaking over a 30 minute period.
The multilamellar vesicle suspension thus formed was extruded
through a 0.2 mm Nucleopore polycarbonate filter 15 times at
room temperature using an Avanti Mini-Extruder (Alabaster, AL,
USA) to obtain the unilamellar vesicle suspension used for the
cisplatin permeability measurements.
The mean vesicle radius of each vesicle preparation was
measured via the dynamic light scattering method using a
Nano Zetasizer (Malvern Instruments, Malvern, UK). Prior to
each measurement of size, the vesicle suspension was diluted
100-fold. The dilutions were performed using the same buﬀer
solution used in the vesicle preparation to avoid any swelling or
shrinkage due to osmotic eﬀects.
Cisplatin permeability coeﬃcient measurements
The kinetics of cisplatin permeation through the membrane of
the vesicles was measured by rapidly mixing a 3.3 mM cisplatin
solution in Tris buﬀer with an equal volume of lipid vesicle
suspension in the same Tris buﬀer solution using an SF-61SX2/
s stopped-flow spectrometer (TgK Scientific, Bradford-on-Avon,
UK). Changes in light scattering of the vesicle suspensions
accompanying movement of water and cisplatin across the
vesicle membrane were detected by monitoring the scattered
light intensity at 901 to the incident light beam. The wavelength
of the incident light was 450 nm. A 75 W Hg–Xe arc lamp
(Hamamatsu Photonics, Hamamatsu City, Japan) was used as the
light source and an R928 side-on photomultiplier (Hamamatsu
Photonics) was used to detect the intensity of the scattered light.
The 3.3 mM cisplatin solutions were prepared by dilution from
5 mM stock solutions which were prepared on the day before the
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stopped-flow measurements to allow sufficient time for ligand
exchange to equilibrate.
At short times (o0.1 s after mixing) there is a rapid increase in
light scattering due to water eﬄux from the vesicles. This occurs
because the external is hypertonic relatively to the intravesicular
solution. At longer times (seconds to tens of seconds) there is
a slower drop in light scattering again as cisplatin diﬀuses into
the vesicles accompanied by water. Similar behaviour has been
observed for the passive diﬀusion of many other solutes across the
membranes of vesicles in the past.17,18 Only the slow drop in light
scattering has been analysed here to determine the cisplatin
permeability coeﬃcient.
Measurements were performed for vesicle suspensions and
cisplatin solutions prepared in buﬀer solutions containing
NaCl concentrations varying from 10 mM to 150 mM. For each
NaCl concentration three to five kinetic traces were averaged
and the observed rate constant, kobs, was determined by fitting
a single exponential time function to the averaged trace. The
apparent cisplatin permeability coeﬃcient, Pd, for each NaCl
concentration was then determined using the following equation:
Pd ¼ kobsr
3
(1)
where r is the average radius of the vesicles, as determined by
dynamic light scattering (see above). The multiplication of kobs by
the factor r/3 comes about from the ratio of the volume of the
vesicle to its surface area.17,18 Small vesicles with small surface
areas allow faster equilibration of the osmotic conditions between
the intra- and extra-vesicular spaces. The factor r/3 accounts for
this eﬀect, and allows the vesicle-size-independent permeability
coeﬃcient to be determined.
Over-expression of the Na+,K+-ATPase in Xenopus oocyctes
Individual oocytes were isolated enzymatically from ovarian
tissue of female Xenopus laevis frogs as described previously.19
The cDNAs of human Na+,K+-ATPase a2- and b1-subunit were
subcloned into an appropriate expression vector (pcDNA3.1X).20
To distinguish the activity of the overexpressed human Na+,K+-
ATPase from the endogenous Na+,K+-ATPase of the oocytes,
the mutations Q116R and N127D were introduced into the
a2-subunit to obtain an ouabain-resistant protein with an IC50
in the millimolar range.21 This protein (a2-Q116R/N127D plus
b1) is referred to as ‘‘RD-WT’’ throughout the text. After linear-
ization of the plasmids, cRNA was synthesized in vitro using the
T7 mMessage mMachine Kit (Ambion). For expression of the
RD-WT enzyme, oocytes were injected with 50 nL cRNA solution
containing 25 ng a2-subunit and 5 ng b1-subunit cRNA using an
electrically driven Nanoject II injection pump (Drummond
Scientific Inc., Broomall, PA). To allow for functional measure-
ments of Na+,K+-ATPase pumping activity, a Na+ loading procedure
was applied to elevate the intracellular Na+ concentration. For this
purpose, RD-WT-expressing oocytes were incubated for 45 min in
Na+ loading buﬀer (110 mM NaCl, 2.5 mM Na-citrate, 2.5 mM
MOPS, 2.5 mM TRIS, pH 7.4) on ice, followed by 30 minutes
recovery on ice in Post Loading Buﬀer (PLB: 100 mM NaCl, 1 mM
CaCl2, 5 mM BaCl2, 5 mM NiCl2 and 2.5 mMMOPS, 2.5 mM TRIS,
pH 7.4). Oocytes were stored in PLB on ice until use. Endogenous
Na+,K+-ATPase expressed by the oocytes was blocked before
carrying out Rb+ uptake measurements by incubating the
oocytes for 15 min at room temperature with a buﬀer containing
100 mM of ouabain, a specific inhibitor of the Na+,K+-ATPase.
During flux measurements, all buﬀers contained 10 mM ouabain.
Atomic absorption measurements of rubidium uptake
For Rb+ uptake studies, Na+-loaded and preincubated oocytes were
transferred into a petri dish filled with Rb+ flux buﬀer (100 mM
NaCl, 5 mM BaCl2, 2 mM MgCl2, 2.5 mM MOPS, 2.5 mM TRIS,
1 mM CaCl2, 10 mM Ouabain, pH 7.4, plus RbCl in concentrations
from 0 to 15 mM) and incubated for exactly 3 min under
temperature control (21 1C in an air-conditioned room). Subse-
quently, oocytes were washed three times in Rb+-free PLB buﬀer
and then transferred to a Petri dish filled with Millipore water.
Afterwards, individual cells are transferred into Eppendorf tubes
filled with 1 mLMillipore water and homogenized using a narrow-
gauge pipette (200 mL). From these probes (which can be stored at
20 1C until analysis with atomic absorption spectrophotometry
(AAS)), 20 mL were transferred by an autosampler into the trans-
versally heated graphite atomizer (THGA) furnace of the AAS
instrument (Perkin Elmer AAnalyst 800), which was equipped with
an appropriate Rb hollow cathode lamp. For each measuring
condition (e.g. Rb+ concentration) at least 10 oocytes from at least
two independent cell preparations were included in analysis. Data
are presented as means  standard error.
Rubidium uptake in the presence of activated intracellular
cisplatin
Since experiments on purified Na+,K+-ATPase as reported by
Hulicˇiak et al.14 indicated that about 50% maximal inhibition
of ATPase activity is achieved at concentrations of activated
cisplatin (cis-diammineaquochlorido platinum(II)) above 4 mM,
we wanted to establish conditions that allow a defined intra-
cellular concentration of activated cisplatin to be achieved.
For this purpose, cisplatin (Sigma-Aldrich, Munich, Germany)
was dissolved in Millipore water at a concentration of 1 mM
and incubated for 24 h at 4 1C in the dark to allow for the
formation of the activated complexes. 50 nL of the 1 mM
activated cisplatin solution was injected into RD-WT expressing
oocytes followed by a 1 h incubation time on ice in Rb+-free PLB
solution to allow for oocyte resealing and equilibration of the
compound within the intracellular space. Since oocytes typically
have between 1 and 1.5 mm diameter, the injection of 50 nL of
1 mM activated cisplatin should create an intracellular concen-
tration between 25 and 100 mM. Cisplatin-injected oocytes were
compared with non-treated cells from the same preparation.
Results and discussion
Kinetics of cisplatin diﬀusion across the lipid vesicle
membrane
On mixing DOPC vesicles with a Tris buﬀer solution containing
cisplatin there is initially a rapid increase in light scattering of
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the sample due to the eﬄux of water from the vesicles (see
Materials andmethods) followed by a slower decrease in scattering
(see Fig. 1) which is attributed to the diﬀusion of cisplatin into the
intravesicular space accompanied by water. As can be seen from
the traces shown in Fig. 1, the kinetics of the slow drop in light
intensity is strongly dependent on the concentration of NaCl
present in the buﬀer, i.e., the passive diﬀusion of cisplatin across
the membrane appears to be significantly slower at low NaCl
concentrations.
However, to compare the kinetics of cisplatin diﬀusion at
diﬀerent NaCl concentrations one must also take into account
the size of the vesicles, which can vary slightly from one
preparation to another, via eqn (1) (see Materials and methods).
Combining the observed rate constants, kobs, obtained by the
fitting of single exponential time functions to the curves shown
in Fig. 1 with the mean vesicle radii of each vesicle preparation
at each NaCl concentration according to eqn (1) yields the
permeability coeﬃcient, Pd, of the vesicles towards cisplatin.
The dependence of the observed value of Pd as a function of the
chloride concentration in the buﬀer is shown in Fig. 2. There it
can be seen that Pd increases steadily as the chloride concentration
of the buﬀer increases until a saturating value of approximately
1.1  106 cm s1 is reached at a Cl concentration of approxi-
mately 100 mM.
The much lower permeability coeﬃcient at low chloride
concentrations can be explained by the dependence of the
stability of the cisplatin complex on the concentration of
chloride in the surrounding medium. The chloride ligands of
the complex are labile and can be easily replaced by H2O
ligands when the chloride concentration of the surroundings
drops. At a chloride concentration of 110 mM, corresponding to
a physiological extracellular chloride concentration, it has been
calculated that 85% of the drug is present in the dichlorido
form, with 11% in the chloridohydroxido form and 4% in the
chloridoaqua form.22–24 Thus, 96% of the drug would be
expected to have an overall neutral charge at a chloride concen-
tration of 110 mM. The neutral charge would facilitate diffusion
of the drug through the nonpolar interior of the lipid bilayer.
However, at low chloride concentrations, such as those present
in the cytoplasm of a cell, where the concentration is typically
only around 4 mM, a much higher percentage of charged forms
would be expected, such as [Pt(NH3)2(H2O)2]
2+. The positive
charge would be expected to significantly reduce the ability of
the drug to pass through the membrane, in agreement with the
much lower Pd values observed at low chloride concentrations
(see Fig. 2).
In addition to the slow diﬀusion of positively charged
cisplatin derivatives out of the cell, once they have been formed
within the cytoplasm their concentration in the cytoplasm
relative to the extracellular medium would be expected to be
further enhanced by the Donnan eﬀect.25 This is due to the
prevalence of negatively over positively charged impermeable
macromolecules within the cell cytoplasm, e.g.DNA and proteins,
which causes an electrostatic attraction for cations in order to
maintain electroneutrality within the cytoplasm. Thus, all cations
which have any permeability towards the membrane, with the
exception of Na+ (which is actively pumped out by the Na+,K+-
ATPase), display a concentration gradient across the cell
membrane with a higher concentration in the cytoplasm relative
to the extracellular fluid. In the absence of any active pumping
mechanisms, an ion’s concentration distribution across the
membrane is determined by the electrical membrane potential
and is given by the Nernst equation.
It has in fact been reported that the accumulation of cisplatin
within the cell cytoplasm is dependent on the magnitude of the
Fig. 1 Kinetics of cisplatin diﬀusion across the membrane of DOPC
vesicles. The kinetic traces show the change in relative light intensity,
DI/I0, observed on mixing of 3.3 mM cisplatin in 5 mM Tris buﬀer with an
equal volume of 5 mM Tris buﬀer containing diﬀerent concentrations of
NaCl. After fitting to single exponential time functions curves a–f were
found to be described by the following kobs values with the corresponding
NaCl concentrations in brackets: 0.020 (0.002) s1 (10 mM), 0.075
(0.003) s1 (50 mM), 0.129 (0.002) s1 (75 mM), 0.203 (0.004) s1
(100 mM), 0.210 (0.003) s1 (125 mM) and 0.210 (0.004) s1 (150 mM).
The temperature was 25 1C and the pH was 7.4.
Fig. 2 Apparent permeability coeﬃcient, Pd, of cisplatin towards the
membrane of DOPC vesicles as a function of the chloride concentration
in the buﬀer solution. The Pd values were calculated from eqn (1) using the
kobs values of the stopped-flow kinetic traces shown in Fig. 1 and average
vesicle radii determined from dynamic light scattering measurements:
134 (2) nm (10 mM), 148 (1) nm (50 mM), 153 (2) nm (75 mM),
152 (2) nm (100 mM), 157 (3) nm (125 mM) and 151 (3) nm (150 mM).
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membrane potential,26 and this observation has sometimes been
presented as evidence that transport of cisplatin into the cell is
protein-mediated.27 However, as just described, the distribution
of any ion which can passively permeate the plasma membrane
is expected to be dependent on the membrane potential. If
uptake was entirely passive, in its uncharged [PtCl2(NH3)2] form
no dependence on the membrane potential would be expected,
but as soon as cisplatin enters the cytoplasm and loses its labile
chloride ions to become positively charged a membrane
potential dependence would become apparent. The accumula-
tion of [Pt(NH3)2(OH2)2]
2+ or [PtCl(NH3)2(OH2)]
+ within the cyto-
plasm would be inhibited by an increase in the membrane
potential, i.e., positive in the cytoplasm. This could explain the
observation that cisplatin accumulation within the cytoplasm is
inhibited on addition of the specific Na+,K+-ATPase inhibitor
ouabain.28 The Na+,K+-ATPase controls the Na+ and K+ distribu-
tions across the plasma membrane and hence indirectly the
membrane potential. If it is inhibited by ouabain, Na+ would
flow into the cell to take up its equilibrium distribution in accord
with the Donnan eﬀect and the membrane potential would
become slightly more positive. The increase in positive charge
within the cytoplasm would disfavour accumulation of
[Pt(NH3)2(H2O)2]
2+ or [PtCl(NH3)2(OH2)]
+, i.e. consistent with
experimental results. Similarly, metabolic inhibitors which
would decrease the production of ATP and hence its supply
to the Na+,K+-ATPase would be expected to decrease accumulation
of [Pt(NH3)2(H2O)2]
2+ or [PtCl(NH3)2(OH2)]
+ within the cytoplasm,
as experimentally observed.28 Such results have also been pre-
viously presented as evidence for protein-mediated uptake of
cisplatin,27 but are in fact consistent with passive diﬀusion across
the membrane.
Another important piece of evidence pointing to a passive
uptake mechanism of cisplatin is the fact that the uptake of
cisplatin is linear with its concentration even up to its solubility
limit, i.e., no saturation is observable.13,29 Finally, structural
analogues of cisplatin have been found to cause no inhibition
of cisplatin uptake, contrary to what one would expect if an
active protein-mediated uptake mechanism was involved.30
These observations, as well as our own data presented here,
therefore, are all consistent with the recent re-evaluation of
platinum–drug entry by Ivy and Kaplan13 that the process
occurs via a mechanism of solubility diffusion through the
membrane.
Rubidium uptake by human Na+,K+-ATPase into Xenopus
oocytes in the presence and absence of activated cisplatin
In its normal mode of function, the Na+,K+-ATPase utilises the
energy released from ATP hydrolysis to actively transport Na+
out of the cell and K+ in. Although the Na+ transport is very
specific, a number of ions can act as congeners replacing K+,
including Rb+.31 Thus, measurements of the kinetics of uptake
of Rb+ by a cell allows one to assess the activity of the Na+,K+-
ATPase and to identify any inhibitory eﬀects of drugs, such as
cisplatin. Measuring Rb+ uptake has advantages over measur-
ing the physiological substrate K+. Firstly, prior to any Rb+
uptake the concentration of Rb+ inside the cell is negligible and
hence there is no background that needs to be subtracted.
Secondly, hollow cathode lamps for Rb+ are available, which
allow the Rb+ level in the cell cytoplasm to be quantified with
high sensitivity and precision via atomic absorption spectro-
photometry. Due to the high intracellular background of K+, the
procedure can’t be performed in the case of K+.
The eﬀect of the rubidium concentration on the Na+,K+-
ATPase-mediated uptake of rubidium ions after 3 minutes
incubation time is shown in Fig. 3. The data in Fig. 3 (upper
panel) show that Rb+ uptake by the heterologously expressed
RD-WT enzyme is drastically inhibited by 10 mM ouabain, a
specific inhibitor of the Na+,K+-ATPase. Although inhibition at
10 mM ouabain is not complete (due to the competition of Rb+
and ouabain for binding to the E2 form of the enzyme), the data
indicate that the uptake is indeed specifically due to the human
RD-WT Na+,K+-ATPase and not to any other transporter.
Fig. 3 Rb+ uptake into RD-WT-expressing Xenopus oocytes. The upper
panel shows the concentration-dependent Rb+ uptake (in picomoles per
oocyte per minute) by human RD-WT Na+,K+-ATPase in the presence of
100 mM extracellular Na+. The specificity of the signal for the RD-WT
enzyme is demonstrated by the substantial inhibition of Rb+ uptake by
10 mM ouabain. The level of passive Rb+ uptake into uninjected control
oocytes of the same batch is shown by column 6 from left. Lower panel: fit
of a Michaelis–Menten-type function to the data from columns 1–5 from
left panel yields a KM value of 0.73 (0.26) mM. Data are given asmeans S.E.
with 18–24 cells from three different cell preparations.
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The significant increase in Rb+ uptake with increasing Rb+
concentration indicates that under the conditions of the
experiments shown in Fig. 3, i.e., over the Rb+ concentration
range 0.5–20 mM and the absence of any K+ in the extracellular
solution, the Rb+ uptake arm of the enzyme’s reaction cycle is a
rate-limiting step for the overall turnover. Therefore, in order to
test for any effect of a drug on Rb+ uptake by the Na+,K+-ATPase,
it is important to keep the Rb+ concentration in this range and
not to go to higher concentrations where Rb+ could reach a
saturating level. Fitting the Rb+ uptake data (Fig. 3, lower panel)
with a Michaelis–Menten-type function yields a KM value for
Rb+-stimulated Rb+ uptake of 2.06 (0.92) mM. However, as
determined from independent control experiments on non-
injected oocytes, a 3 min incubation in Rb+ flux buffers leads
to some non-specific Rb+ uptake, which increases linearly with
[Rb+] and is presumably due to passive diffusion through cation
channels present in the oocyte membrane (the passive Rb+
uptake at 10 mM Rb+ into uninjected control oocytes of the
same batch is shown as column 6 from left in Fig. 3, upper
panel). This non-specific Rb+ uptake reaches about 20% of the
specific (i.e. ouabain-sensitive) Rb+ uptake signal at 20 mM Rb+
(data not shown). If the data are corrected for this non-specific
uptake by linear interpolation (Fig. 3, lower panel), the resulting
KM value is 0.73 (0.26) mM, which agrees well with data in the
literature.32
The eﬀect on RD-WT-mediated Rb+ uptake of the injection of
50 mM pre-activated cisplatin into the cytoplasm of the oocytes
prior to the addition of extracellular Rb+ is shown in Fig. 4.
There, it can be seen that activated cisplatin causes a significant
(about 40–50%) reduction in Rb+ uptake, indicating a cisplatin-
induced inhibition of the Na+,K+-ATPase, with cisplatin acting
on the cytoplasmic face of the enzyme. This is the first direct
evidence for cisplatin-induced inhibition of the Na+,K+-ATPase in
an intact cellular system. However, our data is entirely consistent
with previously published findings obtained using isolated
enzyme fractions of the Na+,K+-ATPase.14,15
The large intracellular loop (loop C45 as termed by Hulicˇiak
et al.14) of the Na+,K+-ATPase a subunit contains 12 conserved
cysteines, which are putative interaction sites of the compound
according to the data of Hulicˇiak et al.14 From MALDI-TOF
peptide mass fingerprinting experiments, these authors suggested
that the highly conserved Cys-367 in the immediate vicinity of the
critical Asp-369, which is intermediately phosphorylated during
the ATP hydrolysis cycle of the enzyme, might be a critical
interaction site. However, this suggestion was not confirmed by
a recent crystal structure of the Na+,K+-ATPase with bound
cisplatin from the same group.33 The crystal structure enabled
seven cisplatin binding sites to be identified. Of these, the most
likely interactions which could lead to inhibition were considered
to be with Met-151, which could block the N-terminal pathway
for the transported ions, or with Met-171, which could hinder
interaction between cytoplasmic domains during the catalytic
cycle. The data presented here set the stage for identifying the
precise amino acid position at which cisplatin exerts its inhibitory
eﬀect on Na+,K+-ATPase by site-directed mutagenesis.
Conclusions
This study has shown that cisplatin is capable of passively
diﬀusing across a lipid bilayer. This can be attributed to the fact
that, when stabilised in the [PtCl2(NH3)2] state by a high
chloride concentration (Z100 mM) in the surrounding medium,
the drug has zero net charge. However, when the chloride
concentration of the medium is reduced, the labile chloride
ions can dissociate from the platinum ion, yielding positively
charged complexes, i.e. first [PtCl(NH3)2(OH2)]
+ and then
[Pt(NH3)2(OH2)2]
2+. The permeability assay results show that
the rate of permeation of these species is significantly lower
than that of the neutral cisplatin. These studies on unilamellar
vesicles do not definitively rule out the possible contribution
of active pathways to the internalisation of cisplatin or its
metabolites, but indicate that passive uptake is likely to play
an important role in contributing to the intracellular pool of
active platinum species.
In the cytoplasm of most animal cells the chloride concen-
tration is only approximately 4 mM, whereas in the extracellular
medium it is approximately 120 mM.34 Therefore, under physio-
logical conditions one would expect a rapid passive diﬀusion of
the neutral cisplatin into the cytoplasm of cells and a signifi-
cantly slower diﬀusion of charged derivatives of cisplatin out of
the cell. Thus, under physiological conditions the positively
charged derivatives would be expected to naturally accumulate
within the cytoplasm. The accumulation of cisplatin within the
cytoplasm by the passive mechanism which we have just
described is shown diagrammatically in Fig. 5. These results
indicate that there is no absolute requirement for any protein-
mediated uptake mechanism, although this doesn’t exclude the
Fig. 4 Cisplatin inhibition of the human RD-WT Na+,K+-ATPase. Prior to
flux experiments 50 nL of a 1 mM aqueous solution of activated cisplatin
were injected into a subset of RD-WT-expressing cells, yielding an intra-
cellular cisplatin concentration between about 25 to 100 mM. Compared to
cells that were not treated with cisplatin, the Rb+ uptake (in picomoles per
oocyte per minute) at 2 mM and 10 mM extracellular Rb+ is reduced by
47% or 39%, respectively. Data are given as means  S.E. with 16–39 cells
from four different cell preparations.
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possibility that some proteins within the cell membrane could
facilitate cisplatin uptake (or extrusion).
Assuming that passive uptake of cisplatin is an important
contributor to internal active platinum species, and that it
occurs through the lipid phase of the membrane, then the
development of resistance is unlikely to occur via a reduction in
the uptake rate, since this could only come about via a change
in the lipid composition of the membrane, which would be
expected to have a detrimental eﬀect on the viability of the cell.
Therefore, if a reduction in drug accumulation in the cytoplasm
does contribute to resistance development, this is much more
likely to come about via an increase in the rate of eﬄux of the
drug out of the cell. Evidence supporting such a mechanism
has recently been presented by Tadini-Buoninsegni et al.,35 who
showed via electrical measurements that the copper ATPases
ATP7A and ATP7B, whose normal function is to pump copper
ions out of the cell, are also capable of actively pumping
platinum out of a cell, with the energy provided by ATP
hydrolysis. Their result provides an explanation for earlier
findings that over-expression of these transporters increases
resistance to cisplatin, as reviewed by Rabik and Dolan.36
The other important finding that we have reported here is
that cisplatin inhibits Na+,K+-ATPase activity in a cellular system
by acting on the enzyme’s cytoplasmic face. Because the Na+,K+-
ATPase plays a crucial role in generating the Na+ gradient across
the membrane which provides the energy source for all amino
acid and sugar transporters of the kidney, inhibition of the
Na+,K+-ATPase would be expected to drastically impair nutrient
reabsorption in the kidney and hence is likely to be in part
responsible for cisplatin’s nephrotoxicity. However, it should be
borne in mind that the kidney is a highly sophisticated and
complex organ, whose membranes contain transporters for a
multitude of substrates. Therefore, it is possible that there is
more than one protein in the kidney which is adversely aﬀected
by the presence of cisplatin.36
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